EVALUATION OF CYTOTOXIC ACTIVITY OF CANAGLIFLOZIN IN HEPG2 CELL LINES
Main Article Content
Keywords
Cytotoxicity, Canagliflozin, hepatocellular carcinoma, IC50
Abstract
This study examines the cytotoxic effects of Canagliflozin on HepG2 cell lines, serving as models for hepatocellular carcinoma (HCC). Canagliflozin was purchased in powder form from CCL pharmaceuticals. HepG2 cells were cultured in DMEM medium and plated in 96-well plates, where Canagliflozin was administered at various concentrations. Cell viability was assessed using crystal violet staining, and the half-maximal inhibitory concentration (IC50) was determined computationally. Results showed moderate cytotoxicity of Canagliflozin, with an IC50 value of 111 µM. The study highlights the potential of Canagliflozin as an anticancer agent and the need for further research to understand its mechanism and optimize therapeutic potential. Overall, this study contributes to the growing evidence supporting the use of Canagliflozin for cancer treatment.
References
2. White JR. Apple Trees to Sodium Glucose Co-Transporter Inhibitors: A Review of SGLT2 Inhibition. Clinical Diabetes [Internet]. 2010 Jan 1 [cited 2024 Sep 15];28(1):5–10. Available from: https://dx.doi.org/10.2337/diaclin.28.1.5
3. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs [Internet]. 2015 Jan 1 [cited 2024 Sep 15];75(1):33–59. Available from: https://link.springer.com/article/10.1007/s40265-014-0337-y
4. Dutka M, Bobiński R, Francuz T, Garczorz W, Zimmer K, Ilczak T, et al. SGLT-2 Inhibitors in Cancer Treatment—Mechanisms of Action and Emerging New Perspectives. Cancers (Basel) [Internet]. 2022 Dec 1 [cited 2024 Sep 15];14(23). Available from: /pmc/articles/PMC9738342/
5. Hawley SA, Ford RJ, Smith BK, Gowans GJ, Mancini SJ, Pitt RD, et al. The Na+/glucose co-transporter inhibitor canagliflozin activates AMP-activated protein kinase by inhibiting mitochondrial function and increasing cellular AMP levels. Diabetes [Internet]. 2016 Sep 1 [cited 2024 Sep 15];65(9):2784. Available from: /pmc/articles/PMC5689380/
6. Zou Z, Zhang Z, Lu C, Wang H. Comparison of time trends in the incidence of primary liver cancer between China and the United States: an age–period–cohort analysis of the Global Burden of Disease 2019. Chin Med J (Engl) [Internet]. 2022 Sep 9 [cited 2024 Sep 15];135(17):2035. Available from: /pmc/articles/PMC9746748/
7. Russo FP, Zanetto A, Pinto E, Battistella S, Penzo B, Burra P, et al. Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand? Int J Mol Sci [Internet]. 2022 Jan 1 [cited 2024 Sep 15];23(1). Available from: /pmc/articles/PMC8745141/
8. Fung J, Lai CL, Yuen MF. Hepatitis B and C virus-related carcinogenesis. Clinical Microbiology and Infection. 2009 Nov 1;15(11):964–70.
9. Ali SA, Donahue RMJ, Qureshi H, Vermund SH. Hepatitis B and hepatitis C in Pakistan: prevalence and risk factors. International Journal of Infectious Diseases. 2009 Jan 1;13(1):9–19.
10. Roderburg C, Özdirik B, Wree A, Demir M, Tacke F. Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies. Hepat Oncol [Internet]. 2020 Jun [cited 2024 Sep 15];7(2). Available from: https://www.tandfonline.com/doi/abs/10.2217/hep-2020-0004
11. Inhibitory effects of canagliflozin on pancreatic cancer are mediated via the downregulation of glucose transporter 1 and lactate dehydrogenase A [Internet]. [cited 2024 Sep 15]. Available from: https://www.spandidos-publications.com/10.3892/ijo.2020.5120
12. Biziotis OD, Tsakiridis EE, Ali A, Ahmadi E, Wu J, Wang S, et al. Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non-small cell lung cancer (NSCLC) through inhibition of HIF-1α. Mol Oncol [Internet]. 2023 Nov 1 [cited 2024 Sep 15];17(11):2235–56. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/1878-0261.13508
13. Nakano D, Kawaguchi T, Iwamoto H, Hayakawa M, Koga H, Torimura T. Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT). PLoS One [Internet]. 2020 Apr 1 [cited 2024 Sep 15];15(4):e0232283. Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0232283
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Mariana Amer
House Officer Khyber Teaching Hospital, Peshawar Pakistan
Shandana Altaf
PhD Pharmacology Assistant Professor Khyber Medical College, Peshawar Pakistan
Muhammad Rehman
MPhil Scholar, Department of Molecular Biology and Genetics, Institute of Basic Medical Science, Khyber Medical University, Peshawar Pakistan
Aniqa Atta
PhD Scholar, Molecular Biology and Genetics, Institute of Basic Medical Science, Khyber Medical University, Peshawar Pakistan